People: ESSA Pharma Inc (EPIX.OQ)
Dr. David Ross Parkinson, M.D., is President, Chief Executive Officer, Director of the Company. He was an Independent Director of ESSA Pharma Inc. Dr. Parkinson is a venture partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as president and chief executive officer of Nodality, a south San Francisco-based biotechnology company focused on the biological characterization of signalling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Until October, 2007, Dr. Parkinson was senior vice-president, oncology research and development, at Biogen Idec. At Biogen Idec, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as vice-president, oncology development, at Amgen, and vice-president, global clinical oncology development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities, leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance and Vectibix. Prior to joining industry, Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as chief of the investigational drug branch, then as acting associate director of the cancer therapy evaluation program. Dr. Parkinson is a past chairman of the Food & Drug Administration (FDA) biologics advisory committee and is a recipient of the FDA's Cody Medal. Dr. Parkinson received his medical degree from the University of Toronto. He completed a hematology fellowship at Royal Victoria Hospital at McGill University in Montreal and was a research fellow at the New England Medical Center at Tufts University in Boston.
|Total Annual Compensation,||--|
|Restricted Stock Awards,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|